gorodenkoff/iStock via Getty Images
- Spruce Biosciences (NASDAQ:SPRB) stock jumped following the announcement that the U.S. FDA has awarded breakthrough therapy designation to its treatment, tralesinidase alfa enzyme replacement therapy (TA-ERT), for sanfilippo syndrome type B.
- The stock experienced multiple trading halts and has skyrocketed by 1,244%, currently priced at $118.61.
- The company is on schedule to submit its biologics license application for TA-ERT targeting MPS IIIB in the first quarter of 2026.
